liver cancer

IRVINE, Calif., May 6, 2026 Helio Genomics announced publication of landmark clinical data demonstrating that its HelioLiver™ multi-analyte blood...

CAMBRIDGE, UK, April 2, 2026 AstraZeneca has announced positive results from the Phase III EMERALD-3 trial, where a combination...

SHANGHAI, China, March 31, 2026 Abbisko Therapeutics has announced that its investigational FGFR4 inhibitor irpagratinib (ABSK-011) has been granted...